CN101076541A - 载脂蛋白a1模拟物及其用途 - Google Patents

载脂蛋白a1模拟物及其用途 Download PDF

Info

Publication number
CN101076541A
CN101076541A CNA2005800311531A CN200580031153A CN101076541A CN 101076541 A CN101076541 A CN 101076541A CN A2005800311531 A CNA2005800311531 A CN A2005800311531A CN 200580031153 A CN200580031153 A CN 200580031153A CN 101076541 A CN101076541 A CN 101076541A
Authority
CN
China
Prior art keywords
peptide mimics
peptide
composition
treatment
promoting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800311531A
Other languages
English (en)
Chinese (zh)
Inventor
W·W·巴乔夫钦
E·A·切法利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CN101076541A publication Critical patent/CN101076541A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2005800311531A 2004-07-16 2005-07-15 载脂蛋白a1模拟物及其用途 Pending CN101076541A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
US60/588,722 2004-07-16

Publications (1)

Publication Number Publication Date
CN101076541A true CN101076541A (zh) 2007-11-21

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800311531A Pending CN101076541A (zh) 2004-07-16 2005-07-15 载脂蛋白a1模拟物及其用途

Country Status (12)

Country Link
US (3) US7569546B2 (cg-RX-API-DMAC10.html)
EP (1) EP1771473B1 (cg-RX-API-DMAC10.html)
JP (1) JP5048486B2 (cg-RX-API-DMAC10.html)
KR (1) KR101185609B1 (cg-RX-API-DMAC10.html)
CN (1) CN101076541A (cg-RX-API-DMAC10.html)
AU (1) AU2005275009B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0513402A (cg-RX-API-DMAC10.html)
CA (1) CA2574007A1 (cg-RX-API-DMAC10.html)
IL (1) IL180733A (cg-RX-API-DMAC10.html)
NO (1) NO20070876L (cg-RX-API-DMAC10.html)
TW (1) TWI377066B (cg-RX-API-DMAC10.html)
WO (1) WO2006020040A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103910802A (zh) * 2014-04-24 2014-07-09 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
CN110831957A (zh) * 2017-01-19 2020-02-21 卫生与公众服务部长代表的美国 Apoc-ii模拟肽

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
ATE533783T1 (de) 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) * 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
MX2011008599A (es) * 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
US20130310304A1 (en) * 2010-06-15 2013-11-21 Matthew C. Lawyer Compositions and methods for the treatment of atherosclerosis
LT2673296T (lt) * 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
KR20260012291A (ko) 2018-07-12 2026-01-26 더 리젠츠 오브 더 유니버시티 오브 미시간 면역 반응을 조절할 수 있는 금속 함유 제형의 조성물 및 방법
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
IL327995A (en) 2023-10-31 2026-06-01 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103910802A (zh) * 2014-04-24 2014-07-09 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
CN110831957A (zh) * 2017-01-19 2020-02-21 卫生与公众服务部长代表的美国 Apoc-ii模拟肽
US11827690B2 (en) 2017-01-19 2023-11-28 Novo Nordisk Inc. ApoC-II mimetic peptides
CN110831957B (zh) * 2017-01-19 2024-02-09 卫生与公众服务部长代表的美国 Apoc-ii模拟肽

Also Published As

Publication number Publication date
US20120259091A1 (en) 2012-10-11
TWI377066B (en) 2012-11-21
TW200612977A (en) 2006-05-01
IL180733A (en) 2013-01-31
JP5048486B2 (ja) 2012-10-17
US8124580B2 (en) 2012-02-28
WO2006020040A2 (en) 2006-02-23
JP2008506709A (ja) 2008-03-06
NO20070876L (no) 2007-03-30
BRPI0513402A (pt) 2008-05-06
EP1771473B1 (en) 2012-12-26
KR101185609B1 (ko) 2012-09-24
US7569546B2 (en) 2009-08-04
US20060069030A1 (en) 2006-03-30
AU2005275009B2 (en) 2011-12-08
EP1771473A2 (en) 2007-04-11
IL180733A0 (en) 2007-06-03
AU2005275009A1 (en) 2006-02-23
WO2006020040A3 (en) 2006-07-06
CA2574007A1 (en) 2006-02-23
KR20070095862A (ko) 2007-10-01
US20100009919A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
EP1771473B1 (en) Apolipoprotein a1 mimetics and uses thereof
EP1496930B1 (en) G-type peptides to ameliorate atherosclerosis
US7148197B2 (en) Orally administered small peptides synergize statin activity
US7199102B2 (en) Orally administered peptides synergize statin activity
JP5241790B2 (ja) アテローム性動脈硬化症を改善する経口投与ペプチド
CN1744909B (zh) 口服给药的肽协同抑制素活性
EP1799242A2 (en) G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
CN1867348B (zh) 口服施用的小肽协同增强抑制素活性
MX2007000571A (en) Apolipoprotein a1 mimetics and uses thereof
AU2003284129B2 (en) Orally administered peptides synergize statin activity
CN1330076A (zh) 内皮素拮抗剂
HK1072896B (en) G-type peptides to ameliorate atherosclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20071121

C20 Patent right or utility model deemed to be abandoned or is abandoned